secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-01-23T23:59:59+00:00
Accession:  0001104659-24-005888
Event type: regulatory
Sentiment:  neutral
Materiality: 0.70
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq grants NRx Pharma transfer to Capital Market; compliance due April 16, 2024
--------------------------------------------------------------------------------

- Nasdaq Hearings Panel grants transfer to Capital Market; must comply with all criteria by April 16, 2024.
- Company believes it has satisfied the $35M market value of listed securities requirement.
- Must evidence compliance with $1.00 minimum bid price for ten consecutive business days by April 16.
- Aims to file first NDA for NRX-100 (ketamine) for acute suicidal depression this quarter.
- Phase 2b/3 trial results for NRX-101 in suicidal bipolar depression expected before compliance date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465924005888/0001104659-24-005888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465924005888/tm243930d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-005888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer